FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135725924> ?p ?o ?g. }

• W3135725924 abstract "Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab is unclear. The present study compared the outcomes and toxicities in patients with metastatic UC after failure of platinum‑based chemotherapy and pembrolizumab, who were selected to receive paclitaxel and carboplatin (TC) chemotherapy, with those in patients who received the best supportive care (BSC). A total of 36 patients received pembrolizumab for metastatic UC at four institutions between January 2018 and August 2019. Of the 21 patients who progressed after pembrolizumab, 7 received TC chemotherapy (TC group) and 14 selected BSC (BSC group). The median observation period was 4.1 months. The 7 aforementioned patients who received TC chemotherapy (4 male and 3 female; median age, 62 years; range, 57‑79 years) were analyzed in the present study. The ECOG performance status was 0 in three patients, 1 in one patient, 2 in two patients and 3 in one patient. Two patients had upper urinary tract UC, two had bladder UC and three had both types of UC. Six patients had visceral metastasis. The number of chemotherapy regimens before pembrolizumab was one in four patients, two in two patients and three in one patient. The objective response rate was 28.6% (partial response, 2 patients; stable disease, 4 patients; progressive disease, 1 patient), the median progression‑free survival time was 3.4 months and the median overall survival time was 10.9 months (vs. 2.7 months in BSC group; P=0.0156). Although grade ≥3 adverse events developed in five patients, there were no treatment‑associated deaths. The present results suggested that TC chemotherapy may be a preferred option for patients who require aggressive treatment after the failure of platinum‑based chemotherapy and pembrolizumab." @default.
• W3135725924 created "2021-03-15" @default.
• W3135725924 creator A5000597213 @default.
• W3135725924 creator A5011256581 @default.
• W3135725924 creator A5012284662 @default.
• W3135725924 creator A5017068775 @default.
• W3135725924 creator A5039626009 @default.
• W3135725924 creator A5051237486 @default.
• W3135725924 creator A5051513242 @default.
• W3135725924 creator A5071222216 @default.
• W3135725924 creator A5073793517 @default.
• W3135725924 creator A5087946125 @default.
• W3135725924 date "2021-03-08" @default.
• W3135725924 modified "2023-10-16" @default.
• W3135725924 title "Paclitaxel and carboplatin chemotherapy after platinum‑based chemotherapy and pembrolizumab for metastatic urothelial carcinoma" @default.
• W3135725924 cites W1500310443 @default.
• W3135725924 cites W1784965045 @default.
• W3135725924 cites W1893740135 @default.
• W3135725924 cites W1939723756 @default.
• W3135725924 cites W2013312714 @default.
• W3135725924 cites W2019607817 @default.
• W3135725924 cites W2027887565 @default.
• W3135725924 cites W2069624577 @default.
• W3135725924 cites W2079315541 @default.
• W3135725924 cites W2092977595 @default.
• W3135725924 cites W2101562875 @default.
• W3135725924 cites W2102116016 @default.
• W3135725924 cites W2103324975 @default.
• W3135725924 cites W2110530327 @default.
• W3135725924 cites W2112320456 @default.
• W3135725924 cites W2114964795 @default.
• W3135725924 cites W2136071329 @default.
• W3135725924 cites W2142540954 @default.
• W3135725924 cites W2144694610 @default.
• W3135725924 cites W2284518822 @default.
• W3135725924 cites W2529904548 @default.
• W3135725924 cites W2588916311 @default.
• W3135725924 cites W2743577629 @default.
• W3135725924 cites W2755210674 @default.
• W3135725924 cites W2764223370 @default.
• W3135725924 cites W2791260187 @default.
• W3135725924 cites W2964014383 @default.
• W3135725924 cites W2966500633 @default.
• W3135725924 cites W2972951159 @default.
• W3135725924 doi "https://doi.org/10.3892/mco.2021.2253" @default.
• W3135725924 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7976390" @default.
• W3135725924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33767860" @default.
• W3135725924 hasPublicationYear "2021" @default.
• W3135725924 type Work @default.
• W3135725924 sameAs 3135725924 @default.
• W3135725924 citedByCount "4" @default.
• W3135725924 countsByYear W31357259242021 @default.
• W3135725924 countsByYear W31357259242022 @default.
• W3135725924 crossrefType "journal-article" @default.
• W3135725924 hasAuthorship W3135725924A5000597213 @default.
• W3135725924 hasAuthorship W3135725924A5011256581 @default.
• W3135725924 hasAuthorship W3135725924A5012284662 @default.
• W3135725924 hasAuthorship W3135725924A5017068775 @default.
• W3135725924 hasAuthorship W3135725924A5039626009 @default.
• W3135725924 hasAuthorship W3135725924A5051237486 @default.
• W3135725924 hasAuthorship W3135725924A5051513242 @default.
• W3135725924 hasAuthorship W3135725924A5071222216 @default.
• W3135725924 hasAuthorship W3135725924A5073793517 @default.
• W3135725924 hasAuthorship W3135725924A5087946125 @default.
• W3135725924 hasBestOaLocation W31357259241 @default.
• W3135725924 hasConcept C121608353 @default.
• W3135725924 hasConcept C126322002 @default.
• W3135725924 hasConcept C143998085 @default.
• W3135725924 hasConcept C2776694085 @default.
• W3135725924 hasConcept C2777701055 @default.
• W3135725924 hasConcept C2778239845 @default.
• W3135725924 hasConcept C2778822529 @default.
• W3135725924 hasConcept C2780057760 @default.
• W3135725924 hasConcept C2780352672 @default.
• W3135725924 hasConcept C2781451048 @default.
• W3135725924 hasConcept C2911057145 @default.
• W3135725924 hasConcept C3019882237 @default.
• W3135725924 hasConcept C71924100 @default.
• W3135725924 hasConceptScore W3135725924C121608353 @default.
• W3135725924 hasConceptScore W3135725924C126322002 @default.
• W3135725924 hasConceptScore W3135725924C143998085 @default.
• W3135725924 hasConceptScore W3135725924C2776694085 @default.
• W3135725924 hasConceptScore W3135725924C2777701055 @default.
• W3135725924 hasConceptScore W3135725924C2778239845 @default.
• W3135725924 hasConceptScore W3135725924C2778822529 @default.
• W3135725924 hasConceptScore W3135725924C2780057760 @default.
• W3135725924 hasConceptScore W3135725924C2780352672 @default.
• W3135725924 hasConceptScore W3135725924C2781451048 @default.
• W3135725924 hasConceptScore W3135725924C2911057145 @default.
• W3135725924 hasConceptScore W3135725924C3019882237 @default.
• W3135725924 hasConceptScore W3135725924C71924100 @default.
• W3135725924 hasIssue "5" @default.
• W3135725924 hasLocation W31357259241 @default.
• W3135725924 hasLocation W31357259242 @default.
• W3135725924 hasOpenAccess W3135725924 @default.
• W3135725924 hasPrimaryLocation W31357259241 @default.
• W3135725924 hasRelatedWork W2569260518 @default.
• W3135725924 hasRelatedWork W2900258459 @default.
• W3135725924 hasRelatedWork W3033877262 @default.
• W3135725924 hasRelatedWork W3046420943 @default.

• next